South Korea Eases Regulations on Autologous Immune Cell Therapy Research

The South Korean Ministry of Health and Welfare has reclassified autologous immune cell culture for clinical research and treatment as “low-risk,” a move designed to accelerate the application process for clinical trial plans. This regulatory shift, announced following the 2026 7th Meeting of the Committee on Advanced Regenerative Medicine and Advanced Biopharmaceuticals on the 25th, removes the requirement for researchers to conduct preliminary clinical studies, potentially shaving two to three years off the development timeline.

What Does the Reclassification Mean for Researchers?

Previously, autologous immune cell therapy was categorized as “medium-risk,” necessitating extensive preparatory clinical research before a formal treatment plan could be submitted. By lowering the risk classification to “low-risk,” the Ministry of Health and Welfare aims to streamline the path to clinical application. This change allows investigators to bypass mandatory multi-year preliminary studies, effectively speeding up the transition from laboratory research to patient-centered clinical trials.

Clinical Trials Approved for Rare and Chronic Conditions

During the session, the committee reviewed six clinical implementation plans and two long-term follow-up investigation plans submitted by regenerative medicine institutions. Of these, four were approved, three were rejected, and one remains under deliberation. The approved trials focus on conditions where existing medical options are limited or ineffective:

• Knee Osteoarthritis: A randomized, double-blind, placebo-controlled study will evaluate the administration of autologous adipose-derived mesenchymal stem cells into the knee joint. Current standard treatments, such as medication and surgery, often provide only temporary relief or carry risks of long-term complications.
• Chronic Neuropathic Pain: Researchers will test the efficacy of autologous stem cells for patients suffering from refractory chronic neuropathic pain. Current pharmacotherapy, including gabapentinoids and antidepressants, often fails to provide sufficient pain control and does not address the underlying cause of the condition.
• Recurrent Glioblastoma: A study will examine the use of autologous natural killer (NK) cells in patients with recurrent glioblastoma. This trial aims to determine the safety and efficacy of the treatment by evaluating progression-free survival in a patient population that currently lacks established standard-of-care treatments.

Why This Regulatory Change Matters

The shift in oversight reflects a broader effort to expand treatment options for patients with serious, rare, and intractable diseases. Kim Dong-ik, chairman of the Committee on Advanced Regenerative Medicine and Advanced Biopharmaceuticals, stated that the committee is prioritizing patient safety while ensuring that clinical decisions are grounded in scientific evidence. The committee’s mandate is to balance the need for medical innovation with the rigorous safety standards required for advanced biological therapies.

Summary of Clinical Developments

The committee intends to continue its evidence-based review process to support the growth of the advanced regenerative medicine sector in South Korea.